Time to response, duration of response, and patient-reported outcomes (PROs) with daratumumab (DARA) plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of the phase 3 MAIA study Meeting Abstract
| Authors: | Facon, T.; Kumar, S.; Plesner, T.; Moreau, P.; Bahlis, N. J.; Goldschmidt, H.; O'Dwyer, M.; Perrot, A.; Christopher; Venner, P.; Weisel, K.; Mace, J. R.; Raje, N. S.; Tiab, M.; Macro, M.; Frenzel, L.; Leleu, X.; Pei, H.; Borgsten, F.; Usmani, S. Z. |
| Abstract Title: | Time to response, duration of response, and patient-reported outcomes (PROs) with daratumumab (DARA) plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of the phase 3 MAIA study |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680302082 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.8044 |
| Notes: | Meeting Abstract: 8044 -- This meeting was also held virtually -- Source: Wos |
